-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on March 25 A few days ago, Sichuan Haisco entered the administrative examination and approval stage with the imitation of 3 types of avanafil tablets, and is expected to win the first imitation.
At the same time, it will become the fourth approved anti-ED oral PDE-5 in China.
Inhibitor.
According to data from Meinenet, physical pharmacies in cities in China are the "main battlefield" of anti-ED drugs.
Sales in 2020 are expected to be close to 3 billion yuan, and Baiyunshan Pharmaceutical General Factory "reigns the king"; 30 new classified anti-ED drugs are in the market.
During the review, two new formulations of sildenafil were unveiled; according to incomplete statistics, 11 innovative anti-ED drugs are under development, and Yangtze River sprints the first domestically produced Class 1 new drug.
At the same time, it will become the fourth approved anti-ED oral PDE-5 in China.
Inhibitor.
According to data from Meinenet, physical pharmacies in cities in China are the "main battlefield" of anti-ED drugs.
Sales in 2020 are expected to be close to 3 billion yuan, and Baiyunshan Pharmaceutical General Factory "reigns the king"; 30 new classified anti-ED drugs are in the market.
During the review, two new formulations of sildenafil were unveiled; according to incomplete statistics, 11 innovative anti-ED drugs are under development, and Yangtze River sprints the first domestically produced Class 1 new drug.
The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will win the first imitation
A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.
Avanafil is an oral fast-acting and highly selective phosphodiesterase-5 (PDE-5) inhibitor.
It was developed by Vivus Corporation of the U.
S.
authorized by Mitsubishi Tanabe Pharmaceutical Co.
, Ltd.
, and was first approved by the FDA for marketing in April 2012.
Used to treat erectile dysfunction (ED).
Avanafil is an oral fast-acting and highly selective phosphodiesterase-5 (PDE-5) inhibitor.
It was developed by Vivus Corporation of the U.
S.
authorized by Mitsubishi Tanabe Pharmaceutical Co.
, Ltd.
, and was first approved by the FDA for marketing in April 2012.
Used to treat erectile dysfunction (ED).
At present, the commonly used anti-ED oral PDE-5 inhibitors mainly include sildenafil, tadalafil, vardenafil and avanafil.
Compared with other PDE-5 inhibitors, avanafil can take effect in the shortest time (15 minutes), which is significantly faster than tadalafil, sildenafil, and vardenafil.
PDE-1 and PDE-6 have higher selectivity, and the side effects are smaller than other types of PDE-5 inhibitors.
Compared with other PDE-5 inhibitors, avanafil can take effect in the shortest time (15 minutes), which is significantly faster than tadalafil, sildenafil, and vardenafil.
PDE-1 and PDE-6 have higher selectivity, and the side effects are smaller than other types of PDE-5 inhibitors.
Production status of new classification of avanafil tablets
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The original research products have not yet been approved to enter the domestic market.
Two companies, Sichuan Haisco and Shanghai Huilun Jiangsu Pharmaceuticals, have submitted applications for the listing of avanafil tablets with imitation 3 types.
Among them, Sichuan Haisco’s products have entered the administrative approval stage first, and are expected to be The first imitation + first review method was approved, and at the same time filled the gap in the market.
Two companies, Sichuan Haisco and Shanghai Huilun Jiangsu Pharmaceuticals, have submitted applications for the listing of avanafil tablets with imitation 3 types.
Among them, Sichuan Haisco’s products have entered the administrative approval stage first, and are expected to be The first imitation + first review method was approved, and at the same time filled the gap in the market.
Domestic marketed anti-ED oral PDE-5 inhibitor
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Menet.
com, in the domestic market, Pfizer’s sildenafil, Eli Lilly’s tadalafil, and Bayer’s vardenafil have all been approved for import, and all generic drugs have been approved for listing.
Tadalafil The competition is fierce, and Haisco's avanafil tablets are expected to become the fourth approved anti-ED oral PDE-5 inhibitor in China.
com, in the domestic market, Pfizer’s sildenafil, Eli Lilly’s tadalafil, and Bayer’s vardenafil have all been approved for import, and all generic drugs have been approved for listing.
Tadalafil The competition is fierce, and Haisco's avanafil tablets are expected to become the fourth approved anti-ED oral PDE-5 inhibitor in China.
Over 3 billion market: Baiyunshan dominates physical pharmacies, hospital market will be shuffled
According to data from Meinnet.
com, in 2019, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and the terminal anti-ED drug market in Chinese urban physical pharmacies exceeded 3.
3 billion yuan, of which physical pharmacies As the "main battlefield", sales in 2020 are expected to be close to 3 billion yuan.
com, in 2019, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and the terminal anti-ED drug market in Chinese urban physical pharmacies exceeded 3.
3 billion yuan, of which physical pharmacies As the "main battlefield", sales in 2020 are expected to be close to 3 billion yuan.
Sales of terminal anti-ED drugs in Chinese public medical institutions and physical pharmacies in Chinese cities (unit: million yuan)
Source: Minet database
The "sales champion" sildenafil is far ahead.
It is expected that the sales of physical pharmacies in Chinese cities will exceed 2.
2 billion yuan in 2020; as more and more tadalafil generic drugs are approved, the market scale of this variety is rapid Expansion; Vardenafil's overall sales are not outstanding due to the small number of production companies.
It is expected that the sales of physical pharmacies in Chinese cities will exceed 2.
2 billion yuan in 2020; as more and more tadalafil generic drugs are approved, the market scale of this variety is rapid Expansion; Vardenafil's overall sales are not outstanding due to the small number of production companies.
TOP3 brands of terminal anti-ED drugs in Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Minet database
In the competitive landscape of terminal anti-ED drug manufacturers in Chinese urban physical pharmacies, Baiyunshan Pharmaceutical General Factory, Pfizer, and Eli Lilly rank the top three; in the brand structure, Baiyunshan Pharmaceutical General Factory’s Sildenafil has a market share of 36.
6%.
First, the market share of original research products has gradually been eroded.
6%.
First, the market share of original research products has gradually been eroded.
In the terminal of public medical institutions in China, import manufacturers still dominate the market, but with the gradual advancement of centralized procurement, the market will usher in a reshuffle.
Tadalafil tablets are the second batch of collectively-sourced varieties and will be implemented in the first half of 2020.
Tasly Diyi and Changchun Haiyue are selected.
Tasly Diyi's products are squeezed into the TOP3 brand for the first time in the first half of 2020; Sildenafil is the third batch of collections.
The selection of varieties will be implemented in the second half of 2020.
Qilu will be selected exclusively.
It is expected to seize part of the market share of the original research products throughout 2020.
Tadalafil tablets are the second batch of collectively-sourced varieties and will be implemented in the first half of 2020.
Tasly Diyi and Changchun Haiyue are selected.
Tasly Diyi's products are squeezed into the TOP3 brand for the first time in the first half of 2020; Sildenafil is the third batch of collections.
The selection of varieties will be implemented in the second half of 2020.
Qilu will be selected exclusively.
It is expected to seize part of the market share of the original research products throughout 2020.
Centralized procurement of anti-ED drugs
Source: Shanghai Sunshine Pharmaceutical Purchasing Network
11 new drugs and 30 new products are under review, Yangzijiang sprints the first domestically produced Class 1 new drug
At present, many domestic pharmaceutical companies have deployed anti-ED treatment fields.
In terms of generic drugs, there are 30 new classifications (in terms of drug name + company name) under review , involving 5 products (in terms of drug name); in terms of innovative drugs, according to incomplete statistics, there are 11 The new drug is undergoing clinical research.
In terms of generic drugs, there are 30 new classifications (in terms of drug name + company name) under review , involving 5 products (in terms of drug name); in terms of innovative drugs, according to incomplete statistics, there are 11 The new drug is undergoing clinical research.
New classification under review to report production of anti-ED drugs
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The competition for tadalafil tablets is fierce, and 13 generic drugs have been approved for production and deemed to have been reviewed.
There are currently 18 companies whose varieties are under review; sildenafil ushered in two new formulations, namely injection and oral For disintegrating tablets, the declared companies are Anrovita Pharmaceuticals and Kelun Pharmaceuticals.
There are currently 18 companies whose varieties are under review; sildenafil ushered in two new formulations, namely injection and oral For disintegrating tablets, the declared companies are Anrovita Pharmaceuticals and Kelun Pharmaceuticals.
Research on innovative anti-ED drugs
Source: China Drug Clinical Trial Publicity Library of Meinenet
Among the 11 innovative anti-ED drugs, Qilu's 2 modified new drug tadalafil oral dissolving film has been applied for marketing and is currently under review and approval.
Among the domestically produced Class 1 new drugs, Yangtze River/Tasly’s Eukanfil Hydrochloride Tablets has made the fastest progress and is currently undergoing Phase III clinical trials.
The product is a PDE-5 inhibitor, developed by Jilin University, Tasly applied for clinical trials, and Yangzijiang carried out clinical research.
It is expected to become the first domestically produced Class 1 new drug against ED.
The product is a PDE-5 inhibitor, developed by Jilin University, Tasly applied for clinical trials, and Yangzijiang carried out clinical research.
It is expected to become the first domestically produced Class 1 new drug against ED.
The TPN729MA tablet jointly developed by Tianfang Pharmaceutical and Shanghai Institute of Materia Medica, Chinese Academy of Sciences is undergoing phase II clinical trials.
Phase I clinical trial data show that the product is superior to the marketed drug sildenafil in terms of activity, selectivity, and side effects.
Phase I clinical trial data show that the product is superior to the marketed drug sildenafil in terms of activity, selectivity, and side effects.
Source: Minet database
Note: The statistics are as of March 22.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
Medical Network News on March 25 A few days ago, Sichuan Haisco entered the administrative examination and approval stage with the imitation of 3 types of avanafil tablets, and is expected to win the first imitation.
At the same time, it will become the fourth approved anti-ED oral PDE-5 in China.
Inhibitor.
According to data from Meinenet, physical pharmacies in cities in China are the "main battlefield" of anti-ED drugs.
Sales in 2020 are expected to be close to 3 billion yuan, and Baiyunshan Pharmaceutical General Factory "reigns the king"; 30 new classified anti-ED drugs are in the market.
During the review, two new formulations of sildenafil were unveiled; according to incomplete statistics, 11 innovative anti-ED drugs are under development, and Yangtze River sprints the first domestically produced Class 1 new drug.
At the same time, it will become the fourth approved anti-ED oral PDE-5 in China.
Inhibitor.
According to data from Meinenet, physical pharmacies in cities in China are the "main battlefield" of anti-ED drugs.
Sales in 2020 are expected to be close to 3 billion yuan, and Baiyunshan Pharmaceutical General Factory "reigns the king"; 30 new classified anti-ED drugs are in the market.
During the review, two new formulations of sildenafil were unveiled; according to incomplete statistics, 11 innovative anti-ED drugs are under development, and Yangtze River sprints the first domestically produced Class 1 new drug.
The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will win the first imitation
A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.
Avanafil is an oral fast-acting and highly selective phosphodiesterase-5 (PDE-5) inhibitor.
It was developed by Vivus Corporation of the U.
S.
authorized by Mitsubishi Tanabe Pharmaceutical Co.
, Ltd.
, and was first approved by the FDA for marketing in April 2012.
Used to treat erectile dysfunction (ED).
Avanafil is an oral fast-acting and highly selective phosphodiesterase-5 (PDE-5) inhibitor.
It was developed by Vivus Corporation of the U.
S.
authorized by Mitsubishi Tanabe Pharmaceutical Co.
, Ltd.
, and was first approved by the FDA for marketing in April 2012.
Used to treat erectile dysfunction (ED).
At present, the commonly used anti-ED oral PDE-5 inhibitors mainly include sildenafil, tadalafil, vardenafil and avanafil.
Compared with other PDE-5 inhibitors, avanafil can take effect in the shortest time (15 minutes), which is significantly faster than tadalafil, sildenafil, and vardenafil.
PDE-1 and PDE-6 have higher selectivity, and the side effects are smaller than other types of PDE-5 inhibitors.
Compared with other PDE-5 inhibitors, avanafil can take effect in the shortest time (15 minutes), which is significantly faster than tadalafil, sildenafil, and vardenafil.
PDE-1 and PDE-6 have higher selectivity, and the side effects are smaller than other types of PDE-5 inhibitors.
Production status of new classification of avanafil tablets
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The original research products have not yet been approved to enter the domestic market.
Two companies, Sichuan Haisco and Shanghai Huilun Jiangsu Pharmaceuticals, have submitted applications for the listing of avanafil tablets with imitation 3 types.
Among them, Sichuan Haisco’s products have entered the administrative approval stage first, and are expected to be The first imitation + first review method was approved, and at the same time filled the gap in the market.
Two companies, Sichuan Haisco and Shanghai Huilun Jiangsu Pharmaceuticals, have submitted applications for the listing of avanafil tablets with imitation 3 types.
Among them, Sichuan Haisco’s products have entered the administrative approval stage first, and are expected to be The first imitation + first review method was approved, and at the same time filled the gap in the market.
Domestic marketed anti-ED oral PDE-5 inhibitor
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Menet.
com, in the domestic market, Pfizer’s sildenafil, Eli Lilly’s tadalafil, and Bayer’s vardenafil have all been approved for import, and all generic drugs have been approved for listing.
Tadalafil The competition is fierce, and Haisco's avanafil tablets are expected to become the fourth approved anti-ED oral PDE-5 inhibitor in China.
com, in the domestic market, Pfizer’s sildenafil, Eli Lilly’s tadalafil, and Bayer’s vardenafil have all been approved for import, and all generic drugs have been approved for listing.
Tadalafil The competition is fierce, and Haisco's avanafil tablets are expected to become the fourth approved anti-ED oral PDE-5 inhibitor in China.
Over 3 billion market: Baiyunshan dominates physical pharmacies, hospital market will be shuffled
According to data from Meinnet.
com, in 2019, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and the terminal anti-ED drug market in Chinese urban physical pharmacies exceeded 3.
3 billion yuan, of which physical pharmacies As the "main battlefield", sales in 2020 are expected to be close to 3 billion yuan.
com, in 2019, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and the terminal anti-ED drug market in Chinese urban physical pharmacies exceeded 3.
3 billion yuan, of which physical pharmacies As the "main battlefield", sales in 2020 are expected to be close to 3 billion yuan.
Sales of terminal anti-ED drugs in Chinese public medical institutions and physical pharmacies in Chinese cities (unit: million yuan)
Source: Minet database
The "sales champion" sildenafil is far ahead.
It is expected that the sales of physical pharmacies in Chinese cities will exceed 2.
2 billion yuan in 2020; as more and more tadalafil generic drugs are approved, the market scale of this variety is rapid Expansion; Vardenafil's overall sales are not outstanding due to the small number of production companies.
It is expected that the sales of physical pharmacies in Chinese cities will exceed 2.
2 billion yuan in 2020; as more and more tadalafil generic drugs are approved, the market scale of this variety is rapid Expansion; Vardenafil's overall sales are not outstanding due to the small number of production companies.
TOP3 brands of terminal anti-ED drugs in Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Minet database
In the competitive landscape of terminal anti-ED drug manufacturers in Chinese urban physical pharmacies, Baiyunshan Pharmaceutical General Factory, Pfizer, and Eli Lilly rank the top three; in the brand structure, Baiyunshan Pharmaceutical General Factory’s Sildenafil has a market share of 36.
6%.
First, the market share of original research products has gradually been eroded.
6%.
First, the market share of original research products has gradually been eroded.
In the terminal of public medical institutions in China, import manufacturers still dominate the market, but with the gradual advancement of centralized procurement, the market will usher in a reshuffle.
Tadalafil tablets are the second batch of collectively-sourced varieties and will be implemented in the first half of 2020.
Tasly Diyi and Changchun Haiyue are selected.
Tasly Diyi's products are squeezed into the TOP3 brand for the first time in the first half of 2020; Sildenafil is the third batch of collections.
The selection of varieties will be implemented in the second half of 2020.
Qilu will be selected exclusively.
It is expected to seize part of the market share of the original research products throughout 2020.
Tadalafil tablets are the second batch of collectively-sourced varieties and will be implemented in the first half of 2020.
Tasly Diyi and Changchun Haiyue are selected.
Tasly Diyi's products are squeezed into the TOP3 brand for the first time in the first half of 2020; Sildenafil is the third batch of collections.
The selection of varieties will be implemented in the second half of 2020.
Qilu will be selected exclusively.
It is expected to seize part of the market share of the original research products throughout 2020.
Centralized procurement of anti-ED drugs
Source: Shanghai Sunshine Pharmaceutical Purchasing Network
11 new drugs and 30 new products are under review, Yangzijiang sprints the first domestically produced Class 1 new drug
At present, many domestic pharmaceutical companies have deployed anti-ED treatment fields.
In terms of generic drugs, there are 30 new classifications (in terms of drug name + company name) under review , involving 5 products (in terms of drug name); in terms of innovative drugs, according to incomplete statistics, there are 11 The new drug is undergoing clinical research.
In terms of generic drugs, there are 30 new classifications (in terms of drug name + company name) under review , involving 5 products (in terms of drug name); in terms of innovative drugs, according to incomplete statistics, there are 11 The new drug is undergoing clinical research.
New classification under review to report production of anti-ED drugs
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The competition for tadalafil tablets is fierce, and 13 generic drugs have been approved for production and deemed to have been reviewed.
There are currently 18 companies whose varieties are under review; sildenafil ushered in two new formulations, namely injection and oral For disintegrating tablets, the declared companies are Anrovita Pharmaceuticals and Kelun Pharmaceuticals.
There are currently 18 companies whose varieties are under review; sildenafil ushered in two new formulations, namely injection and oral For disintegrating tablets, the declared companies are Anrovita Pharmaceuticals and Kelun Pharmaceuticals.
Research on innovative anti-ED drugs
Source: China Drug Clinical Trial Publicity Library of Meinenet
Among the 11 innovative anti-ED drugs, Qilu's 2 modified new drug tadalafil oral dissolving film has been applied for marketing and is currently under review and approval.
Among the domestically produced Class 1 new drugs, Yangtze River/Tasly’s Eukanfil Hydrochloride Tablets has made the fastest progress and is currently undergoing Phase III clinical trials.
The product is a PDE-5 inhibitor, developed by Jilin University, Tasly applied for clinical trials, and Yangzijiang carried out clinical research.
It is expected to become the first domestically produced Class 1 new drug against ED.
The product is a PDE-5 inhibitor, developed by Jilin University, Tasly applied for clinical trials, and Yangzijiang carried out clinical research.
It is expected to become the first domestically produced Class 1 new drug against ED.
The TPN729MA tablet jointly developed by Tianfang Pharmaceutical and Shanghai Institute of Materia Medica, Chinese Academy of Sciences is undergoing phase II clinical trials.
Phase I clinical trial data show that the product is superior to the marketed drug sildenafil in terms of activity, selectivity, and side effects.
Phase I clinical trial data show that the product is superior to the marketed drug sildenafil in terms of activity, selectivity, and side effects.
Source: Minet database
Note: The statistics are as of March 22.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
Medical Network News on March 25 A few days ago, Sichuan Haisco entered the administrative examination and approval stage with the imitation of 3 types of avanafil tablets, and is expected to win the first imitation.
At the same time, it will become the fourth approved anti-ED oral PDE-5 in China.
Inhibitor.
According to data from Meinenet, physical pharmacies in cities in China are the "main battlefield" of anti-ED drugs.
Sales in 2020 are expected to be close to 3 billion yuan, and Baiyunshan Pharmaceutical General Factory "reigns the king"; 30 new classified anti-ED drugs are in the market.
During the review, two new formulations of sildenafil were unveiled; according to incomplete statistics, 11 innovative anti-ED drugs are under development, and Yangtze River sprints the first domestically produced Class 1 new drug.
At the same time, it will become the fourth approved anti-ED oral PDE-5 in China.
Inhibitor.
According to data from Meinenet, physical pharmacies in cities in China are the "main battlefield" of anti-ED drugs.
Sales in 2020 are expected to be close to 3 billion yuan, and Baiyunshan Pharmaceutical General Factory "reigns the king"; 30 new classified anti-ED drugs are in the market.
During the review, two new formulations of sildenafil were unveiled; according to incomplete statistics, 11 innovative anti-ED drugs are under development, and Yangtze River sprints the first domestically produced Class 1 new drug.
The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will win the first imitation
The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will win the first imitation A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.
Avanafil is an oral fast-acting and highly selective phosphodiesterase-5 (PDE-5) inhibitor.
It was developed by Vivus Corporation of the U.
S.
authorized by Mitsubishi Tanabe Pharmaceutical Co.
, Ltd.
, and was first approved by the FDA for marketing in April 2012.
Used to treat erectile dysfunction (ED).
Avanafil is an oral fast-acting and highly selective phosphodiesterase-5 (PDE-5) inhibitor.
It was developed by Vivus Corporation of the U.
S.
authorized by Mitsubishi Tanabe Pharmaceutical Co.
, Ltd.
, and was first approved by the FDA for marketing in April 2012.
Used to treat erectile dysfunction (ED).
At present, the commonly used anti-ED oral PDE-5 inhibitors mainly include sildenafil, tadalafil, vardenafil and avanafil.
Compared with other PDE-5 inhibitors, avanafil can take effect in the shortest time (15 minutes), which is significantly faster than tadalafil, sildenafil, and vardenafil.
PDE-1 and PDE-6 have higher selectivity, and the side effects are smaller than other types of PDE-5 inhibitors.
Compared with other PDE-5 inhibitors, avanafil can take effect in the shortest time (15 minutes), which is significantly faster than tadalafil, sildenafil, and vardenafil.
PDE-1 and PDE-6 have higher selectivity, and the side effects are smaller than other types of PDE-5 inhibitors.
Production status of new classification of avanafil tablets
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The original research products have not yet been approved to enter the domestic market.
Two companies, Sichuan Haisco and Shanghai Huilun Jiangsu Pharmaceuticals, have submitted applications for the listing of avanafil tablets with imitation 3 types.
Among them, Sichuan Haisco’s products have entered the administrative approval stage first, and are expected to be The first imitation + first review method was approved, and at the same time filled the gap in the market.
Two companies, Sichuan Haisco and Shanghai Huilun Jiangsu Pharmaceuticals, have submitted applications for the listing of avanafil tablets with imitation 3 types.
Among them, Sichuan Haisco’s products have entered the administrative approval stage first, and are expected to be The first imitation + first review method was approved, and at the same time filled the gap in the market.
Domestic marketed anti-ED oral PDE-5 inhibitor
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Menet.
com, in the domestic market, Pfizer’s sildenafil, Eli Lilly’s tadalafil, and Bayer’s vardenafil have all been approved for import, and all generic drugs have been approved for listing.
Tadalafil The competition is fierce, and Haisco's avanafil tablets are expected to become the fourth approved anti-ED oral PDE-5 inhibitor in China.
com, in the domestic market, Pfizer’s sildenafil, Eli Lilly’s tadalafil, and Bayer’s vardenafil have all been approved for import, and all generic drugs have been approved for listing.
Tadalafil The competition is fierce, and Haisco's avanafil tablets are expected to become the fourth approved anti-ED oral PDE-5 inhibitor in China.
Over 3 billion market: Baiyunshan dominates physical pharmacies, hospital market will be shuffled
Over 3 billion market: Baiyunshan dominates physical pharmacies, hospital market will be shuffled According to data from Meinnet.
com, in 2019, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and the terminal anti-ED drug market in Chinese urban physical pharmacies exceeded 3.
3 billion yuan, of which physical pharmacies As the "main battlefield", sales in 2020 are expected to be close to 3 billion yuan.
Hospital hospital hospital pharmacy pharmacy pharmacycom, in 2019, China’s urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and the terminal anti-ED drug market in Chinese urban physical pharmacies exceeded 3.
3 billion yuan, of which physical pharmacies As the "main battlefield", sales in 2020 are expected to be close to 3 billion yuan.
Sales of terminal anti-ED drugs in Chinese public medical institutions and physical pharmacies in Chinese cities (unit: million yuan)
Source: Minet database
The "sales champion" sildenafil is far ahead.
It is expected that the sales of physical pharmacies in Chinese cities will exceed 2.
2 billion yuan in 2020; as more and more tadalafil generic drugs are approved, the market scale of this variety is rapid Expansion; Vardenafil's overall sales are not outstanding due to the small number of production companies.
It is expected that the sales of physical pharmacies in Chinese cities will exceed 2.
2 billion yuan in 2020; as more and more tadalafil generic drugs are approved, the market scale of this variety is rapid Expansion; Vardenafil's overall sales are not outstanding due to the small number of production companies.
TOP3 brands of terminal anti-ED drugs in Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Minet database
In the competitive landscape of terminal anti-ED drug manufacturers in Chinese urban physical pharmacies, Baiyunshan Pharmaceutical General Factory, Pfizer, and Eli Lilly rank the top three; in the brand structure, Baiyunshan Pharmaceutical General Factory’s Sildenafil has a market share of 36.
6%.
First, the market share of original research products has gradually been eroded.
6%.
First, the market share of original research products has gradually been eroded.
In the terminal of public medical institutions in China, import manufacturers still dominate the market, but with the gradual advancement of centralized procurement, the market will usher in a reshuffle.
Tadalafil tablets are the second batch of collectively-sourced varieties and will be implemented in the first half of 2020.
Tasly Diyi and Changchun Haiyue are selected.
Tasly Diyi's products are squeezed into the TOP3 brand for the first time in the first half of 2020; Sildenafil is the third batch of collections.
The selection of varieties will be implemented in the second half of 2020.
Qilu will be selected exclusively.
It is expected to seize part of the market share of the original research products throughout 2020.
Tadalafil tablets are the second batch of collectively-sourced varieties and will be implemented in the first half of 2020.
Tasly Diyi and Changchun Haiyue are selected.
Tasly Diyi's products are squeezed into the TOP3 brand for the first time in the first half of 2020; Sildenafil is the third batch of collections.
The selection of varieties will be implemented in the second half of 2020.
Qilu will be selected exclusively.
It is expected to seize part of the market share of the original research products throughout 2020.
Centralized procurement of anti-ED drugs
Source: Shanghai Sunshine Pharmaceutical Purchasing Network
Medicine Medicine 11 new drugs and 30 new products are under review, Yangzijiang sprints the first domestically produced Class 1 new drug
11 new drugs and 30 new products are under review, Yangzijiang sprints the first domestically produced Class 1 new drug At present, many domestic pharmaceutical companies have deployed anti-ED treatment fields.
In terms of generic drugs, there are 30 new classifications (in terms of drug name + company name) under review , involving 5 products (in terms of drug name); in terms of innovative drugs, according to incomplete statistics, there are 11 The new drug is undergoing clinical research.
Drugs Drugs Drugs enterprise business enterpriseIn terms of generic drugs, there are 30 new classifications (in terms of drug name + company name) under review , involving 5 products (in terms of drug name); in terms of innovative drugs, according to incomplete statistics, there are 11 The new drug is undergoing clinical research.
New classification under review to report production of anti-ED drugs
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The competition for tadalafil tablets is fierce, and 13 generic drugs have been approved for production and deemed to have been reviewed.
There are currently 18 companies whose varieties are under review; sildenafil ushered in two new formulations, namely injection and oral For disintegrating tablets, the declared companies are Anrovita Pharmaceuticals and Kelun Pharmaceuticals.
There are currently 18 companies whose varieties are under review; sildenafil ushered in two new formulations, namely injection and oral For disintegrating tablets, the declared companies are Anrovita Pharmaceuticals and Kelun Pharmaceuticals.
Research on innovative anti-ED drugs
Source: China Drug Clinical Trial Publicity Library of Meinenet
Among the 11 innovative anti-ED drugs, Qilu's 2 modified new drug tadalafil oral dissolving film has been applied for marketing and is currently under review and approval.
Among the domestically produced Class 1 new drugs, Yangtze River/Tasly’s Eukanfil Hydrochloride Tablets has made the fastest progress and is currently undergoing Phase III clinical trials.
The product is a PDE-5 inhibitor, developed by Jilin University, Tasly applied for clinical trials, and Yangzijiang carried out clinical research.
It is expected to become the first domestically produced Class 1 new drug against ED.
The product is a PDE-5 inhibitor, developed by Jilin University, Tasly applied for clinical trials, and Yangzijiang carried out clinical research.
It is expected to become the first domestically produced Class 1 new drug against ED.
The TPN729MA tablet jointly developed by Tianfang Pharmaceutical and Shanghai Institute of Materia Medica, Chinese Academy of Sciences is undergoing phase II clinical trials.
Phase I clinical trial data show that the product is superior to the marketed drug sildenafil in terms of activity, selectivity, and side effects.
Phase I clinical trial data show that the product is superior to the marketed drug sildenafil in terms of activity, selectivity, and side effects.
Source: Minet database
Note: The statistics are as of March 22.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
